Dual-selectin-targeted USMI has previously been used to differentiate different disease activities of inflammation and to assess treatment effects, and USMI findings were validated using standard references of ex vivo histology and P- and E-selectin expression in various rodent and swine models of IBD [17,19,20,21]. This evidence concerns the gene OCA2 and inflammatory bowel disease.